India's top 100 pharma report 2014-15 sales up 7.2%, EBDITA 5.3% - PharmaBiz

15 July 2015

Combined full-year profits for the top 100 pharma companies dipped to 1.8% on the back of issues with the US Food and Drug Association, stringent price controls and a competitive global market among others, a PharmaBiz report showed.

Net sales

Adjusted net sales for the top 100 companies increased by 7.2% to 1,712.01 billion rupees ($26.1 billion) from 1,597.47 billion rupees.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical